No Data
Chinese Health: 2024 Annual Report Summary
Chinese Health: 2024 Annual Report
In 2024, China Health (301408.SZ) plans to increase its Net income by 20.09% to 0.138 billion yuan, proposing a dividend of 1 yuan per share.
On April 24th, Gelonghui reported that Chinese Health (301408.SZ) released its annual report for 2024. The company's revenue reached a new high in 2024, amounting to 0.19 billion yuan, which is a 19.34% increase compared to the same period last year; the net income attributable to the parent company's owners was 0.138 billion yuan, a 20.09% increase year-on-year; the net income attributable to the parent company's owners after deducting non-recurring gains and losses was 0.129 billion yuan, a 21.81% increase compared to the same period last year, with research and development expenses at 29.3873 million yuan, a 21.46% increase from the previous year. The company's cash flow from operations has continued to improve, and the quality of operations is steadily increasing.
The Recent CN¥492m Market Cap Decrease Is Likely to Have Disappointed Insiders Invested in Anhui Huaren Health Pharmaceutical Co., Ltd. (SZSE:301408)
China Health (301408.SZ): Not involved in the production, sales, and related industrial layout of exoskeleton Siasun Robot&Automation.
On April 9th, Gelonghui reported that Huaren Health (301408.SZ) stated on its investor interaction platform that the company focuses on the pharmaceutical health sector and has not engaged in the production, sales, or related industrial layout of exoskeleton robots. In the future, we will continue to pay attention to emerging technologies and market dynamics within the Industry, actively exploring opportunities that align with the company's Global Strategy.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Could The Market Be Wrong About Anhui Huaren Health Pharmaceutical Co., Ltd. (SZSE:301408) Given Its Attractive Financial Prospects?
